The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.

At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.

Take a look through some of the notable data presentations at this year's ESMO Congress.

The completion of the first procedure marks the beginning of a controlled US commercial release.

Butterfly Medical has also submitted a premarket approval application to the FDA.

Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.